

Nduka M Amankulor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/582505/publications.pdf>

Version: 2024-02-01

45
papers

2,340
citations

394421

19
h-index

345221

36
g-index

45
all docs

45
docs citations

45
times ranked

4696
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. <i>Genome Biology</i> , 2017, 18, 234.	8.8	448
2	Osteopontin-CD44 Signaling in the Glioma Perivascular Niche Enhances Cancer Stem Cell Phenotypes and Promotes Aggressive Tumor Growth. <i>Cell Stem Cell</i> , 2014, 14, 357-369.	11.1	411
3	Mutant IDH1 regulates the tumor-associated immune system in gliomas. <i>Genes and Development</i> , 2017, 31, 774-786.	5.9	313
4	Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). <i>Blood</i> , 2017, 130, 1430-1440.	1.4	131
5	IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. <i>Neuro-Oncology</i> , 2016, 18, 1402-1412.	1.2	126
6	Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. <i>Neuro-Oncology</i> , 2016, 18, 379-387.	1.2	101
7	Induction of Robust Type-1 CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC. <i>Clinical Cancer Research</i> , 2015, 21, 286-294.	7.0	92
8	The incidence and patterns of hardware failure after separation surgery in patients with spinal metastatic tumors. <i>Spine Journal</i> , 2014, 14, 1850-1859.	1.3	86
9	Associations of meningioma molecular subgroup and tumor recurrence. <i>Neuro-Oncology</i> , 2021, 23, 783-794.	1.2	83
10	Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. <i>Journal of Neurosurgery</i> , 2020, 133, 1345-1354.	1.6	83
11	Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV. <i>Molecular Therapy</i> , 2015, 23, 99-107.	8.2	69
12	Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	49
13	Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 255.	8.6	45
14	TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 637146.	4.8	32
15	GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 214-222.	4.4	28
16	Ommaya reservoir with ventricular catheter placement for chemotherapy with frameless and pinless electromagnetic surgical neuronavigation. <i>Clinical Neurology and Neurosurgery</i> , 2015, 130, 61-66.	1.4	27
17	Long-Term Outcomes After Stereotactic Radiosurgery for Spine Metastases: Radiation Dose-Response for Late Toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 602-609.	0.8	26
18	Tumor Bed Radiosurgery Following Resection and Prior Stereotactic Radiosurgery for Locally Persistent Brain Metastasis. <i>Frontiers in Oncology</i> , 2015, 5, 84.	2.8	25

#	ARTICLE	IF	CITATIONS
19	Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. <i>JCI Insight</i> , 2019, 4, .	5.0	24
20	Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1550-1561.	4.1	22
21	Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. <i>Cancer Research</i> , 2019, 79, 4026-4041.	0.9	16
22	Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome. <i>Nature Cancer</i> , 2022, 3, 629-648.	13.2	16
23	The Utility of Early Postoperative Head Computed Tomography in Brain Tumor Surgery: A Retrospective Analysis of 755 Cases. <i>World Neurosurgery</i> , 2018, 111, e206-e212.	1.3	11
24	The Subventricular Zone in Glioblastoma: Genesis, Maintenance, and Modeling. <i>Frontiers in Oncology</i> , 2022, 12, 790976.	2.8	11
25	A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care. <i>Journal of Neuro-Oncology</i> , 2021, 151, 103-112.	2.9	10
26	Hyalinizing Clear Cell Carcinoma with Biopsy-Proven Spinal Metastasis: Case Report and Review of Literature. <i>World Neurosurgery</i> , 2016, 90, 699.e7-699.e10.	1.3	8
27	Oncolytic HSV Vectors and Anti-Tumor Immunity. <i>Current Issues in Molecular Biology</i> , 2021, 41, 381-468.	2.4	8
28	Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient. <i>Immunotherapy</i> , 2020, 12, 763-769.	2.0	7
29	A Novel 5-Aminolevulinic Acid-Enabled Surgical Loupe System—A Consecutive Brain Tumor Series of 11 Cases. <i>Operative Neurosurgery</i> , 2022, 22, 298-304.	0.8	7
30	Autophagy inhibition is the next step in the treatment of glioblastoma patients following the Stupp era. <i>Cancer Gene Therapy</i> , 2020, 28, 971-983.	4.6	6
31	Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators. <i>Neurosurgery</i> , 2021, 89, 129-132.	1.1	5
32	Machine Learning Identification of Immunotherapy Targets in Low-Grade Glioma using RNA Sequencing Expression Data. <i>World Neurosurgery</i> , 2022, , .	1.3	4
33	Venous Thromboembolism Anticoagulation Prophylaxis Timing in Patients Undergoing Craniotomy for Tumor. <i>Neurosurgery Open</i> , 2021, 2, .	0.2	3
34	The Evolving Role of Induced Pluripotent Stem Cells and Cerebral Organoids in Treating and Modeling Neurosurgical Diseases. <i>World Neurosurgery</i> , 2021, 155, 171-179.	1.3	3
35	In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas. <i>Neurosurgical Focus</i> , 2022, 52, E3.	2.3	2
36	Headlight and loupe-based fluorescein detection system in brain tumor surgery; a first-in-human experience. <i>Journal of Neurosurgical Sciences</i> , 2021, , .	0.6	1

#	ARTICLE	IF	CITATIONS
37	PATH-39. ASSOCIATIONS OF GENOMIC SUBGROUP WITH RECURRENCE IN LOW-GRADE MENINGIOMAS. Neuro-Oncology, 2020, 22, ii172-ii173.	1.2	1
38	IB-03 * IDH MUTANT GLIOMAS ARE RESISTANT TO NATURAL KILLER CELL-MEDIATED CYTOLYSIS. Neuro-Oncology, 2014, 16, v107-v107.	1.2	0
39	2036 Extracellular matrix as a novel approach to glioma therapy. Journal of Clinical and Translational Science, 2018, 2, 11-12.	0.6	0
40	IMMU-18. TARGETING THE PD1 AND TIGIT CHECKPOINT PATHWAYS FOR ADULT AND PEDIATRIC GLIOMAS. Neuro-Oncology, 2018, 20, vi125-vi125.	1.2	0
41	TMIC-13. EFFICACY OF RETINOIC ACID IN REVERSING IMMUNE EVASION IN IDH MUTANT GLIOMAS. Neuro-Oncology, 2018, 20, vi258-vi258.	1.2	0
42	Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutationâ€“positive melanoma with metastases to the brain (BRV116521).. Journal of Clinical Oncology, 2014, 32, TPS9112-TPS9112.	1.6	0
43	Isolation and characterization of exosomes from IDH mutant gliomas.. Journal of Clinical Oncology, 2019, 37, 152-152.	1.6	0
44	MNGI-09. MENINGIOMA WITH MULTIPLE DRIVERS: GENOMIC LANDSCAPE AND CLINICAL CORRELATIONS. Neuro-Oncology, 2019, 21, vi141-vi141.	1.2	0
45	A liquid fraction of extracellular matrix inhibits glioma cell viability <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2022, 13, 426-438.	1.8	0